Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.

Nature communications - 24 Apr 2020

Lei Changhai, Qian Kewen, Li Tian, Zhang Sheng, Fu Wenyan, Ding Min, Hu Shi

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Betacoronavirus
Share to Cross Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to Inhibitory Concentration 50

Share to Membrane Fusion

Share to Receptors, Virus

Share to Severe acute respiratory syndrome-related coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 32332765
DOI: 10.1038/s41467-020-16048-4
PMCID: PMC7265355

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.PMID 32332765Read ↗

SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infectionSemantic proximity Read ↗

The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and AntibodiesSemantic proximity Read ↗

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralizationSemantic proximity Read ↗

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.Semantic proximity Read ↗

ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodiesSemantic proximity Read ↗

Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion proteinSemantic proximity Read ↗

Sequence variation of SARS-CoV-2 spike protein may facilitate stronger interaction with ACE2 promoting high infectivitySemantic proximity Read ↗

Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion proteinSemantic proximity Read ↗

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernSemantic proximity Read ↗

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.Semantic proximity Read ↗

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesSemantic proximity Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.